Septerna (NASDAQ:SEPN) Insider Sells $171,699.55 in Stock

Septerna, Inc. (NASDAQ:SEPN) insider Samira Shaikhly sold 5,935 shares of Septerna stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $28.93, for a total value of $171,699.55. Following the completion of the transaction, the insider owned 793 shares of the company’s stock, valued at approximately $22,941.49. This represents a 88.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Samira Shaikhly also recently made the following trade(s):

• On Tuesday, May 26th, Samira Shaikhly sold 11,798 shares of Septerna stock. The stock was sold at an average price of $30.06, for a total value of $354,647.88.

Septerna Trading Down 0.7%

SEPN opened at $31.15 on Friday. The firm has a market cap of $1.40 billion, a P/E ratio of -38.46 and a beta of 2.39. Septerna, Inc. has a 12 month low of $9.85 and a 12 month high of $32.63. The stock has a 50-day moving average of $26.15 and a 200 day moving average of $26.47.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.23. The company had revenue of $26.52 million during the quarter, compared to analyst estimates of $16.98 million. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%. On average, research analysts forecast that Septerna, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Group One Trading LLC boosted its position in shares of Septerna by 111.8% during the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after buying an additional 8,955 shares during the period. Global Retirement Partners LLC purchased a new position in shares of Septerna during the fourth quarter valued at approximately $35,000. Russell Investments Group Ltd. purchased a new position in shares of Septerna during the third quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Septerna during the fourth quarter valued at approximately $53,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Septerna during the fourth quarter valued at approximately $61,000.

Analyst Ratings Changes

Several research analysts recently commented on SEPN shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $60.00 price target on shares of Septerna in a research report on Tuesday, March 10th. Zacks Research upgraded Septerna from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Stifel Nicolaus began coverage on Septerna in a research report on Friday, May 1st. They set a “buy” rating and a $43.00 target price for the company. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Septerna in a research report on Wednesday, May 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Septerna presently has an average rating of “Moderate Buy” and an average target price of $43.13.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.